

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND



**MARCH 28, 2024
RANDOLPH TOWNSHIP HALL
9:30 AM
AGENDA AND REPORTS**

Meeting Location: Township of Randolph Municipal Building

502 Millbrook Ave.
Randolph, NJ 07869
Tel: 973.989.7100
Fax: 973.989.7096

STATEMENT OF COMPLIANCE WITH OPEN PUBLIC MEETINGS ACT

NOTICE OF THIS MEETING WAS GIVEN BY (1) SENDING SUFFICIENT NOTICE HERewith TO THE STAR LEDGER, (2) FILING ADVANCE WRITTEN NOTICE OF THIS MEETING WITH THE CLERK/ADMINISTRATOR OF EACH MEMBER MUNICIPALITY AND (3) POSTING A COPY OF THE MEETING NOTICE ON THE PUBLIC BULLETIN BOARD OF ALL MEMBER MUNICIPALITIES.

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND
AGENDA MEETING: MARCH 28, 2024
RANDOLPH TOWNSHIP HALL
9:30 AM

MEETING CALLED TO ORDER - OPEN PUBLIC MEETING NOTICE READ

FLAG SALUTE

ROLL CALL OF 2024 EXECUTIVE COMMITTEE

2024 Executive Committee	
Scott Heck, Chair	Borough of Ringwood
Tom Russo, Secretary	Town of Newton
Barbara Russo	Township of Berkeley Heights
Tammy Smith	Knowlton BOE
Silvio Esposito	Township of Hanover
Carinne Piccolo- Kaufer	Township of Hardyston
Greg Poff	Borough of Randolph*
Executive Committee Alternates:	
Adam Brewer	Township of Pequannock
Cathy Shanahan	Township of West Milford
Dina Valente - Stoel	Borough of Lincoln Park

APPROVAL OF MINUTES: *January 25, 2024*

Open Appendix I

CORRESPONDENCE - None

REPORTS:

EXECUTIVE DIRECTOR (PERMA)

Monthly Report.....Page 4
 Resolution 24-15: Joining the Cooperative Pricing SystemPage 14

PROGRAM MANAGER- (Vozza Agency)

Monthly Report.....Page 19

TREASURER - (Michael Soccio)

February and March 2024 Voucher ListPage 30
 Confirmation of Claims Paid/Certification of Transfers
 Ratification of Treasurers Report
 Resolution 24-16: February and March 2024 Bills ListPage 37

ATTORNEY - (Fred Semrau)

Monthly ReportPage N/A

WELLNESS COORIDNATOR - (Marianne Eskilson)

Monthly Report.....Page 38

NETWORK & THIRD PARTY ADMINISTRATOR - (Aetna - Jason Silverstein)

Monthly Report.....Page 43

PRESCRIPTION ADMINISTRATOR - (Express Scripts-Charles Yuk)

Monthly ReportPage 48

DENTAL ADMINISTRATOR - (Delta Dental)

Monthly ReportPage 56

OLD BUSINESS

NEW BUSINESS

PUBLIC COMMENT

**RESOLUTION - EXECUTIVE SESSION FOR CERTAIN SPECIFIED PURPOSES
PERSONNEL - CLAIMS - LITIGATION**

MEETING ADJOURNED

**NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND
EXECUTIVE DIRECTOR'S REPORT
MARCH 28, 2024**

FINANCE

PRO FORMA REPORTS

- **Fast Track Financial Report** – as of December 31, 2023 & January 31, 2024 (page 6)

COOPERATIVE PRICING SYSTEM – JOINING MEMBER

In 2023, the MRHIF and its affiliates sought approval from the NJ Office of the Comptroller to issue an RFP for TPA Services for the local Funds. Approval was not given, as the Comptroller's office felt that MRHIF did not have the authority to procure a claims agent being utilized by the local Funds. To secure TPA services for PY 2024, the local Funds each performed a 1-year contract for TPA services in the hopes that group purchasing would be permitted for a longer contract starting in 2025.

We have reviewed with the MRHIF QPA and Attorney who agree that the Funds may enter into a Cooperative Pricing Agreement with a lead agent. The SNJREBF will be the lead agent as they currently have existing contracts with both HIF TPAs and Medicare Advantage providers.

The concept of the HIF Cooperative Pricing System was presented to the MRHIF Commissioners by the MRHIF Attorney and received full support.

Two entities are needed to form – the Southern HIF and BMED will be the initial members of the System. A resolution to join is included, along with the agreement to be signed by the Fund Chair.

Note: We do need to elect a NJHIF representative to the System.

DIRECT MEMBER BILLING

We are aware that some of our entities, their risk managers and the Program Manager's Office have been contacted by direct bill enrollees regarding delays and incorrect 2024 rates they're being billed. 2024 coupon payment information were sent the first week of March.

On behalf of our office and WEX (North HIF Benefits Administrator), we apologize for any concerns or challenges this may have created for you and your members. Most importantly, please be assured that no member coverage was impacted by these delays/errors.

PERMA is working with WEX to take the following corrective steps to improve this experience going forward:

- 1) Senior leadership meeting with PERMA and WEX.
 - a. Customer Service
 - b. Resources

- c. Project plan tool
- d. Suppressing automated communications
- 2) Evaluation of current process for improvement.
- 3) Creation of additional tools to streamline process and eliminate manual intervention.
- 4) Proactive HIF outreach to membership in Executive Committee meetings and direct to membership.

As we continue to evaluate processes and implement improvements, we will keep the Executive Committee updated.

We want to recognize and thank, the Program Manager's office for fielding the related service outreaches, which was beyond the normal volume.

FEBRUARY MRHIF MEETING

The MRHIF had their reorganization meeting on February 15, 2024. Commissioner Esposito was present to represent the Fund.

Below are some of the key highlights:

- 1. The Fund Attorney provided an overview of the **Cooperative Pricing System Initiative**.
- 2. Approval was granted for the Fund Attorney to manage the **Cooperative Pricing System** filing.
- 3. Approval to go out to RFP for a **Data Warehouse system** was approved.
- 4. Approval to go out to **RFP for Reinsurer** for multi-year contract was approved.

FINANCIAL DISCLOSURE STATEMENTS

The Financial Disclosure notice emails will be sent out in April. The deadline for filing is April 30, 2024. Please file as soon as you get the email.

Reminder: A separate filing will need to be done for each position – HIF Fund Commissioner, JIF Fund Commissioner, Local Elected Official, etc.

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND						
FINANCIAL FAST TRACK REPORT						
		AS OF	December 31, 2023			
		THIS MONTH	YTD CHANGE	PRIOR YEAR END	FUND BALANCE	
1.	UNDERWRITING INCOME	4,686,270	51,211,275	788,537,107	839,748,382	
2.	CLAIM EXPENSES					
	Paid Claims	4,287,092	42,274,872	656,480,325	698,755,198	
	IBNR	274,916	819,479	2,857,945	3,677,424	
	Less Specific Excess	-	(704,204)	(20,853,873)	(21,558,076)	
	Less Aggregate Excess	-	-	-	-	
TOTAL CLAIMS		4,562,008	42,390,148	638,484,398	680,874,546	
3.	EXPENSES					
	MA & HMO Premiums	274,409	2,909,472	23,211,850	26,121,322	
	Excess Premiums	320,429	3,616,487	31,388,303	35,004,790	
	Administrative	230,375	2,759,907	53,003,855	55,763,762	
TOTAL EXPENSES		825,213	9,285,866	107,604,008	116,889,873	
4.	UNDERWRITING PROFIT/(LOSS) (1-2-3)	(700,951)	(464,738)	42,448,701	41,983,963	
5.	INVESTMENT INCOME	58,531	623,148	4,877,619	5,500,768	
6.	DIVIDEND INCOME	0	282,649	5,929,601	6,212,250	
7.	STATUTORY PROFIT/(LOSS) (4+5+6)	(642,421)	441,059	53,255,922	53,696,981	
8.	DIVIDEND	1,991,409	1,991,409	40,510,183	42,501,592	
9.	Transferred Surplus	0	0	0	0	
STATUTORY SURPLUS (7-8+9)		(2,633,830)	(1,550,350)	12,745,739	11,195,389	
SURPLUS (DEFICITS) BY FUND YEAR						
Closed		Surplus	(1,948,886)	(1,465,604)	11,259,935	9,794,331
		Cash	(1,351,948)	(1,948,441)	14,526,795	12,578,355
2022		Surplus	9,407	167,297	1,485,803	1,653,100
		Cash	(6,198)	871,938	698,529	1,570,467
2023		Surplus	(694,351)	(252,043)		(252,043)
		Cash	(771,580)	870,567		870,567
TOTAL SURPLUS (DEFICITS)		(2,633,830)	(1,550,350)	12,745,738	11,195,388	
TOTAL CASH		(2,129,726)	(205,936)	15,225,324	15,019,389	
CLAIM ANALYSIS BY FUND YEAR						
TOTAL CLOSED YEAR CLAIMS		1,045	256,138	606,242,143	606,498,280	
FUND YEAR 2022						
	Paid Claims	14,051	3,631,818	29,590,988	33,222,806	
	IBNR	(17,148)	(2,857,945)	2,857,945	-	
	Less Specific Excess	0	(713,460)	(206,676)	(920,136)	
	Less Aggregate Excess	0	0	0	0	
TOTAL FY 2022 CLAIMS		(3,097)	60,414	32,242,257	32,302,670	
FUND YEAR 2023						
	Paid Claims	4,271,996	38,396,172		38,396,172	
	IBNR	292,064	3,677,424		3,677,424	
	Less Specific Excess	0	0		0	
	Less Aggregate Excess	0	0		0	
TOTAL FY 2023 CLAIMS		4,564,060	42,073,596		42,073,596	
COMBINED TOTAL CLAIMS		4,562,008	42,390,148	638,484,399	680,874,547	
This report is based upon information which has not been audited nor certified by an actuary and as such may not truly represent the condition of the fund.						

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND													
RATIOS													
		FY2023											
INDICES	2022	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
Cash Position	15,225,324	\$ 14,433,593	\$ 15,575,818	\$ 15,539,414	\$ 17,032,185	\$ 17,340,361	\$ 16,646,714	\$ 18,267,684	\$ 15,096,688	\$ 16,708,870	\$ 16,467,384	\$ 17,149,115	\$ 15,019,389
IBNR	2,857,945	\$ 2,916,741	\$ 2,675,111	\$ 2,741,413	\$ 2,878,108	\$ 3,005,113	\$ 3,118,240	\$ 3,191,437	\$ 3,267,962	\$ 3,423,972	\$ 3,510,142	\$ 3,402,508	\$ 3,677,424
Assets	19,094,495	\$ 19,118,296	\$ 18,894,098	\$ 19,381,323	\$ 19,646,647	\$ 19,402,893	\$ 19,689,784	\$ 19,896,787	\$ 18,936,453	\$ 19,319,513	\$ 19,716,074	\$ 19,568,649	\$ 17,877,237
Liabilities	6,348,758	\$ 6,232,119	\$ 5,449,234	\$ 5,457,966	\$ 5,538,377	\$ 5,632,683	\$ 5,682,818	\$ 5,676,496	\$ 5,727,002	\$ 5,856,418	\$ 5,909,115	\$ 5,739,432	\$ 6,681,850
Surplus	12,745,737	\$ 12,886,177	\$ 13,444,864	\$ 13,923,357	\$ 14,108,270	\$ 13,770,210	\$ 14,006,966	\$ 14,220,290	\$ 13,209,451	\$ 13,463,095	\$ 13,806,959	\$ 13,829,217	\$ 11,195,387
Claims Paid -- Month	939,338	\$ 2,890,944	\$ 2,883,392	\$ 2,982,906	\$ 3,196,437	\$ 3,659,320	\$ 3,247,036	\$ 3,183,687	\$ 4,522,064	\$ 3,857,038	\$ 3,488,977	\$ 4,075,980	\$ 4,287,092
Claims Budget -- Month	2,795,937	\$ 3,106,718	\$ 3,112,136	\$ 3,129,419	\$ 3,293,429	\$ 3,424,269	\$ 3,422,574	\$ 3,440,954	\$ 3,529,394	\$ 3,763,115	\$ 3,816,780	\$ 3,813,992	\$ 3,818,377
Claims Paid -- YTD	33,390,346	\$ 2,890,944	\$ 5,774,336	\$ 8,757,242	\$ 11,953,678	\$ 15,612,998	\$ 18,860,034	\$ 22,043,721	\$ 26,565,786	\$ 30,422,824	\$ 33,911,801	\$ 37,987,780	\$ 42,274,872
Claims Budget -- YTD	33,709,481	\$ 3,106,718	\$ 6,218,854	\$ 9,348,273	\$ 12,641,702	\$ 16,065,971	\$ 19,488,545	\$ 22,934,490	\$ 26,460,717	\$ 30,343,137	\$ 34,152,472	\$ 37,920,602	\$ 41,738,979
RATIOS													
Cash Position to Claims Paid	16.21	4.99	5.40	5.21	5.33	4.74	5.13	5.74	3.34	4.33	4.72	4.21	3.50
Claims Paid to Claims Budget -- Month	0.34	0.93	0.93	0.95	0.97	1.07	0.95	0.93	1.28	1.02	0.91	1.07	1.12
Claims Paid to Claims Budget -- YTD	0.99	0.93	0.93	0.94	0.95	0.97	0.97	0.96	1.00	1	0.99	1	1.01
Cash Position to IBNR	5.33	4.95	5.82	5.67	5.92	5.77	5.34	5.72	4.62	4.88	4.69	5.04	4.08
Assets to Liabilities	3.01	3.07	3.47	3.55	3.55	3.44	3.46	3.51	3.31	3.3	3.34	3.41	2.68
Surplus as Months of Claims	4.56	4.15	4.32	4.45	4.28	4.02	4.09	4.13	3.74	3.58	3.62	3.63	2.93
IBNR to Claims Budget -- Month	1.02	0.94	0.86	0.88	0.87	0.88	0.91	0.93	0.93	0.91	0.92	0.89	0.96

North Jersey Municipal Employee Benefits Fund

CONSOLIDATED BALANCE SHEET

AS OF DECEMBER 31, 2023

BY FUND YEAR

	NJMEB 2023	NJMEB 2022	CLOSED YEAR	FUND BALANCE
ASSETS				
Cash & Cash Equivalents	870,567	1,570,467	12,578,355	15,019,389
Assessments Receivable (Prepaid)	1,780,510	(3,147)	-	1,777,363
Interest Receivable	3,593	3,240	25,844	32,678
Specific Excess Receivable	-	82,539	-	82,539
Aggregate Excess Receivable	-	-	-	-
Dividend Receivable	-	-	-	-
Prepaid Admin Fees	-	-	-	-
Other Assets	965,268	0	-	965,268
Total Assets	3,619,939	1,653,100	12,604,198	17,877,237
LIABILITIES				
Accounts Payable	969	0	-	969
IBNR Reserve	3,677,424	-	-	3,677,424
A4 Retiree Surcharge	10,094	-	-	10,094
Dividends Payable	-	-	37,440	37,440
Retained Dividends	-	-	2,772,428	2,772,428
Accrued/Other Liabilities	183,495	(0)	-	183,495
Total Liabilities	3,871,982	0	2,809,868	6,681,850
EQUITY				
Surplus / (Deficit)	(252,043)	1,653,100	9,794,331	11,195,387
Total Equity	(252,043)	1,653,100	9,794,331	11,195,387
Total Liabilities & Equity	3,619,939	1,653,100	12,604,198	17,877,237
BALANCE	(0)	-	-	-

This report is based upon information which has not been audited nor certified
by an actuary and as such may not truly represent the condition of the fund.
Fund Year allocation of claims have been estimated.

North Jersey Municipal Employee Benefits Fund						
2023 Budget Report						
AS OF DECEMBER 31, 2023						
				Cumulative	\$ Variance	% Variance
	Cumulative	Annual	Latest Filed	Expensed		
LINE ITEMS						
Medical Claims Aetna	37,038,022	37,038,022	30,452,833			
Medical Claims Aetna BOEs	544,146	544,146	596,684			
Subtotal Medical Claims	37,582,168	37,582,168	31,049,517	37,289,664	292,504	1%
Prescription Claims	3,491,475	3,491,475	2,882,428			
Less Rebates	(1,047,443)	(1,047,443)	(864,728)			
Subtotal Rx Claims	2,444,032	2,444,032	2,017,700	3,183,485	(739,453)	-30%
Dental Claims	1,712,779	1,712,779	1,706,182	1,586,972	125,807	7%
Subtotal	41,738,979	41,738,979	34,773,399	42,060,121	(321,142)	-1%
Medicare Advantage - United	566,231	566,231	620,112	Included in Medicare Advantage-Aetna below		
Medicare Advantage - Aetna	2,343,558	2,343,558	1,602,509	2,909,472	318	0%
Reinsurance						
Specific	3,616,487	3,616,487	3,254,218	3,616,487	0	0%
Wellness	235,000	235,000	235,000	186,327	48,673	21%
Total Loss Fund	48,500,255	48,500,255	40,485,238	48,772,407	(272,151)	-1%
Expenses						
Legal	20,000	20,000	20,000	31,304	(11,303)	-57%
Treasurer	22,974	22,974	22,974	22,974	(0)	0%
Administrator	447,534	447,534	403,683	447,534	-	0%
Program Manager -	587,232	587,232	509,764	537,221	50,011	9%
Program Manager - Brokerage	735,938	735,938	562,835	750,268	(14,331)	-2%
TPA - Aetna	799,697	799,697	660,153	799,697	-	0%
Wellness Coordinator	25,000	25,000	25,000	25,000	(1)	0%
Dental TPA	74,137	74,137	72,673	74,137	(0)	0%
Actuary	12,485	12,485	12,485	12,480	5	0%
Auditor	17,462	17,462	17,462	17,462	0	0%
Subtotal Expenses	2,742,458	2,742,458	2,307,029	2,718,077	24,381	1%
Miscellaneous and Special Services						
Misc/Cont(incl. A4 surcharge)	23,100	23,100	23,100	21,874	1,226	5%
Claims and Service Audits	40,000	40,000	40,000	0	-	0%
Affordable Care Act Taxes	11,569	11,569	9,314	10,368	1,201	10%
Subtotal Misc/Sp Svcs	74,669	74,669	72,414	32,242	2,427	3%
Total Expenses	2,817,127	2,817,127	2,379,444	2,750,319	26,807.78	1%
Total Budget	51,317,382	51,317,382	42,864,681	51,522,725	(245,344)	0%

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND						
FINANCIAL FAST TRACK REPORT						
		AS OF	January 31, 2024			
		THIS MONTH	YTD CHANGE		PRIOR YEAR END	FUND BALANCE
1.	UNDERWRITING INCOME	4,976,128	4,976,128		839,748,382	844,724,510
2.	CLAIM EXPENSES					
	Paid Claims	4,646,910	4,646,910		698,742,619	703,389,529
	IBNR	329,884	329,884		3,439,837	3,769,721
	Less Specific Excess	-	-		(21,558,076)	(21,558,076)
	Less Aggregate Excess	-	-		-	-
TOTAL CLAIMS		4,976,793	4,976,793		680,624,380	685,601,173
3.	EXPENSES					
	MA & HMO Premiums	286,497	286,497		26,120,996	26,407,493
	Excess Premiums	343,622	343,622		35,004,790	35,348,412
	Administrative	271,027	271,027		55,755,221	56,026,248
TOTAL EXPENSES		901,146	901,146		116,881,007	117,782,153
4.	UNDERWRITING PROFIT/(LOSS) (1-2-3)	(901,812)	(901,812)		42,242,995	41,341,183
5.	INVESTMENT INCOME	48,747	48,747		5,500,768	5,549,515
6.	DIVIDEND INCOME	-	-		6,212,250	6,212,250
7.	STATUTORY PROFIT/(LOSS) (4+5+6)	(853,065)	(853,065)		53,956,013	53,102,948
8.	DIVIDEND	-	-		42,501,592	42,501,592
9.	Transferred Surplus	-	-			-
STATUTORY SURPLUS (7-8+9)		(853,065)	(853,065)		11,454,421	10,601,356
SURPLUS (DEFICITS) BY FUND YEAR						
Closed		Surplus	30,759	30,759	9,794,331	9,825,090
		Cash	(16,941)	(16,941)	12,578,355	12,561,414
2022		Surplus	(46,362)	(46,362)	1,653,100	1,606,738
		Cash	36,179	36,179	1,570,467	1,606,646
2023		Surplus	(1,318,441)	(1,318,441)	6,990	(1,311,451)
		Cash	(1,419,325)	(1,419,325)	870,567	(548,758)
2024		Surplus	480,979	480,979		480,979
		Cash	(942,200)	(942,200)		(942,200)
TOTAL SURPLUS (DEFICITS)		(853,065)	(853,065)		11,454,421	10,601,356
TOTAL CASH		(2,342,286)	(2,342,287)		15,019,389	12,677,102
CLAIM ANALYSIS BY FUND YEAR						
TOTAL CLOSED YEAR CLAIMS		6,202	6,202		606,498,280	606,504,482
FUND YEAR 2022						
	Paid Claims	52,770	52,770		33,222,806	33,275,576
	IBNR	-	-		-	-
	Less Specific Excess	-	-		(920,136)	(920,136)
	Less Aggregate Excess	-	-		-	-
TOTAL FY 2022 CLAIMS		52,770	52,770		32,302,670	32,355,440
FUND YEAR 2023						
	Paid Claims	3,078,135	3,078,135		38,383,593	41,461,728
	IBNR	(1,754,317)	(1,754,317)		3,439,837	1,685,520
	Less Specific Excess	-	-		-	-
	Less Aggregate Excess	-	-		-	-
TOTAL FY 2023 CLAIMS		1,323,818	1,323,818		41,823,430	43,147,248
FUND YEAR 2024						
	Paid Claims	1,509,802	1,509,802			1,509,802
	IBNR	2,084,201	2,084,201			2,084,201
	Less Specific Excess	-	-			-
	Less Aggregate Excess	-	-			-
TOTAL FY 2024 CLAIMS		3,594,002	3,594,002			3,594,002
COMBINED TOTAL CLAIMS		4,976,793	4,976,793		680,624,380	685,601,173

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND		
RATIOS		
INDICES	2023	JAN
Cash Position	15,019,389	\$ 12,677,102
IBNR	3,439,837	\$ 3,769,721
Assets	17,889,815	\$ 17,188,251
Liabilities	6,435,395	\$ 6,586,896
Surplus	11,454,420	\$ 10,601,355
Claims Paid -- Month	4,274,514	\$ 4,646,910
Claims Budget -- Month	3,818,377	\$ 4,004,395
Claims Paid -- YTD	42,141,131	\$ 4,646,910
Claims Budget -- YTD	41,738,979	\$ 4,004,395
RATIOS		
Cash Position to Claims Paid	3.51	2.73
Claims Paid to Claims Budget -- Month	1.12	1.16
Claims Paid to Claims Budget -- YTD	1.01	1.16
Cash Position to IBNR	4.37	3.36
Assets to Liabilities	2.78	2.61
Surplus as Months of Claims	3.00	2.65
IBNR to Claims Budget -- Month	0.90	0.94

North Jersey Municipal Employee Benefits Fund						
2024 Budget Report						
AS OF JANUARY 31, 2024						
				Cumulative	\$ Variance	% Variance
	Cumulative	Annual	Latest Filed	Expensed		
LINE ITEMS						
Medical Claims Aetna	3,599,127	47,685,728	39,546,391			
Medical Claims Aetna BOEs	46,656	559,872	595,717			
Subtotal Medical Claims	3,645,783	48,245,600	40,142,108	3,205,865	439,918	12%
Prescription Claims	245,977	3,109,608	2,558,040			
Subtotal Rx Claims	245,977	3,109,608	2,558,040	241,096	4,881	2%
Dental Claims	139,365	1,681,350	1,630,553	147,041	(7,676)	-6%
Subtotal	4,031,125	53,036,558	44,330,701	3,594,002	437,123	11%
Medicare Advantage - United	48,842	578,454	596,569	Included in Medicare Advantage-Aetna below		
Medicare Advantage - Aetna	235,850	3,093,719	2,389,779	286,497	(1,805)	-1%
Reinsurance						
Specific	342,605	4,549,305	3,975,900	343,622	(1,017)	0%
Wellness	23,583	283,000	283,000	23,583	0	0%
Total Loss Fund	4,682,005	61,541,036	51,575,949	4,247,704	434,301	9%
Expenses						
Legal	1,708	20,500	20,500	1,667	41	2%
Treasurer	1,953	23,433	23,433	1,953	(0)	0%
Administrator	41,018	527,632	459,793	41,133	(115)	0%
Program Manager -	54,438	704,341	605,584	50,420	4,019	7%
Program Manager - Brokerage	60,201	(887,948)	717,435	64,372	(4,171)	-7%
TPA - Aetna	74,177	973,752	818,952	74,454	(277)	0%
Wellness Coordinator	2,083	25,000	25,000	2,083	-	0%
Dental TPA	6,500	78,403	78,597	6,657	(157)	-2%
Actuary	1,061	12,735	12,734	1,063	(2)	0%
Auditor	1,484	17,811	17,811	1,484	0	0%
Subtotal Expenses	244,624	1,495,659	2,779,840	245,285	(661)	0%
Miscellaneous and Special Services						
Misc/Cont(incl. A4 surcharge)	3,542	42,500	42,500	0	3,542	100%
Claims and Service Audits	3,333	40,000	40,000	0	-	0%
Affordable Care Act Taxes	1,073	14,087	11,847	1,073	0	0%
Subtotal Misc/Sp Svcs	7,948	96,587	94,347	1,073	3,542	45%
Total Expenses	252,572	1,592,246	2,874,188	246,358	2,880.68	1%
Total Budget	4,934,578	63,133,282	54,450,137	4,494,062	437,182	9%

North Jersey Municipal Employee Benefits Fund

CONSOLIDATED BALANCE SHEET

AS OF JANUARY 31, 2024

BY FUND YEAR

	NJMEB 2023	NJMEB 2022	NJMEB 2021	CLOSED YEAR	FUND BALANCE
ASSETS					
Cash & Cash Equivalents	(942,200)	(548,758)	1,606,646	12,561,414	12,677,102
Assessments Receivable (Prepaid)	3,209,444	278,851	(3,147)	-	3,485,148
Interest Receivable	-	3,591	3,238	25,728	32,557
Specific Excess Receivable	-	-	-	-	-
Aggregate Excess Receivable	-	-	-	-	-
Dividend Receivable	-	-	-	-	-
Prepaid Admin Fees	2,122	-	-	-	2,122
Other Assets	321,954	669,367	-	-	991,322
Total Assets	2,591,320	403,052	1,606,737	12,587,141	17,188,251
LIABILITIES					
Accounts Payable	-	(0)	-	-	(0)
IBNR Reserve	2,084,201	1,685,520	-	-	3,769,720
A4 Retiree Surcharge	-	10,094	-	-	10,094
Dividends Payable	-	-	-	129,165	129,165
Retained Dividends	-	-	-	2,632,887	2,632,887
Accrued/Other Liabilities	26,140	18,890	-	-	45,030
Total Liabilities	2,110,341	1,714,503	-	2,762,052	6,586,896
EQUITY					
Surplus / (Deficit)	480,979	(1,311,451)	1,606,737	9,825,090	10,601,355
Total Equity	480,979	(1,311,451)	1,606,737	9,825,090	10,601,355
Total Liabilities & Equity	2,591,320	403,052	1,606,737	12,587,141	17,188,251
BALANCE	-	-	-	-	-

This report is based upon information which has not been audited nor certified
by an actuary and as such may not truly represent the condition of the fund.
Fund Year allocation of claims have been estimated.

RESOLUTION NO. 24-15

**NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND
RESOLUTION FOR MEMBER PARTICIPATION IN THE HEALTH INSURANCE
COOPERATIVE PRICING SYSTEM
A RESOLUTION AUTHORIZING THE
NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND TO ENTER INTO A
COOPERATIVE PRICING AGREEMENT**

WHEREAS, N.J.S.A. 40A:11- 11(5), N.J.S.A. 18A:18A-11 and N.J.A.C. 5:34-7.3 authorizes contracting units to establish a Cooperative Pricing System and to enter into Cooperative Pricing Agreements for its administration; and

WHEREAS, the Southern New Jersey Regional Employee Benefits Fund, hereinafter referred to as the "Lead Agency " has offered voluntary participation in a Cooperative Pricing System for the purchase of third-party claim administration services;

WHEREAS, on March 28, 2024 the Executive Committee of the North Jersey Municipal Employee Benefits Fund duly considered participation in the Health Insurance Cooperative Pricing System for the provision and performance of goods and services;

NOW, THEREFORE BE IT RESOLVED as follows:

TITLE

This RESOLUTION shall be known and may be cited as the Cooperative Pricing Resolution of the Health Insurance Cooperative Pricing System

AUTHORITY

Pursuant to the provisions of N.J.S.A.40A: 11-11(5), N.J.S.A. 18A:18A-11and N.J.A.C. 5:34-7.3 the Chairman is hereby authorized to enter into a Cooperative Pricing Agreement with the Lead Agency and to execute and deliver a Joinder Agreement and such other documents as are necessary to confirm membership and participation in the Cooperative Pricing System.

CONTRACTING UNIT

The Lead Agency shall be responsible for complying with the provisions of the local Public Contracts Law (N.J.S.A. 40A:11-1 et seq.) and all other provisions of the revised statutes of the State of New Jersey.

EFFECTIVE DATE

This resolution shall take effect immediately upon passage.

CERTIFICATION

I hereby certify the foregoing to be an original resolution adopted by the Executive Committee of the North Jersey Municipal Employee Benefits Fund at a meeting held on March 28, 2024.

ADOPTED: March 28, 2024

BY: _____
CHAIRPERSON

ATTEST:

SECRETARY

HEALTH INSURANCE COOPERATIVE PRICING SYSTEM

JOINDER AGREEMENT

THIS JOINDER AGREEMENT (this "Joinder"), is being executed by _____, (the "Fund") a joint health insurance fund formed pursuant to N.J. S.A. 40A:10-36 (18A:18B-1 et seq.) , having offices at 9 Campus Drive, Suite 216, Parsippany, NJ 07054, in order to become a member of the HEALTH INSURANCE COOPERATIVE PRICING SYSTEM formed on _____, 2024 (the "HICPS") in order to obtain third party claim administration services for medical, dental and vision health benefits, prescription drug pharmacy benefit manager services and Medicare Advantage Plan providers.

WHEREAS, Paragraph 1(c) of the HICPS Agreement requires any contracting unit desiring to become a member of the HICPS to adopt a resolution in accordance with applicable laws substantially in the same form attached to this Agreement as Exhibit A (the "Resolution") approving its membership in the HICPS and the execution of this Joinder; and

WHEREAS, the Fund has adopted the Resolution and transmitted a certified copy to the Lead Agency (as defined in the HICPS Agreement), for delivery to the State of New Jersey pursuant to applicable law; and

WHEREAS, the Fund has reviewed the terms of the HICPA Agreement and desires to be bound thereby;

NOW THEREFORE, for and in consideration of the promises herein contained and intending to be legally bound, the Fund, covenants and agrees as follows:

1. The Fund hereby acknowledges, consents to, joins in and agrees to be bound by the HICPS Agreement and all of the terms and conditions thereof all of which are incorporated herein by this reference, as if the Fund had been an original signatory thereto. A copy of the HICPS Agreement has been provided to the Fund, the receipt of which is hereby acknowledged.

IN WITNESS WHEREOF, the Fund has properly executed this Joinder as of the date noted below.

ATTEST:

By: _____ By: _____

Name:

Title:

Date: _____

ACCEPTED AND AGREED:

Health Insurance Cooperative Pricing System

By: _____
Chairman of Executive Committee of the Lead Agency

Date: _____

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND

Year: 2024

<u>Monthly Items</u>	<u>Filing Status</u>
Budget	Filed
Assessments	Filed
Actuarial Certification	Filed
Reinsurance Policies	Filed
Fund Commissioners	Filed
Fund Officers	Filed
Renewal Resolutions	Filed
Indemnity and Trust	Filed
New Members	N/A
Withdrawals	N/A
Risk Management Plan and By Laws	Filed
Cash Management Plan	Filed
Unaudited Financials	9/30/2023 Filed
Annual Audit	12/31/2022 filed
Budget Changes	N/A
Transfers	N/A
Additional Assessments	N/A
Professional Changes	N/A
Officer Changes	N/A
RMP Changes	Filed
Bylaw Amendments	N/A
Contracts	Filed
Benefit Changes	N/A



Office of the Program Manager
North Jersey Municipal Benefits Fund



An Insurance and Risk Management Corporation

77 Market Street • P.O. Box 100 • Park Ridge, New Jersey 07656 • Phone (201) 573-1000 • Fax (201) 573-1004

TO: Executive Committee
North Jersey Municipal Employee Benefits Fund

FROM: The Vozza Agency- Office of the Program Manager

DATE: March 28, 2024

RE: Program Manager's Report

- Town Visits/Meetings/Plan Change Requests
- Enrollment, Eligibility and Billing
- Direct Bill Billing Issues – Complaints
- New Member Submissions
- Data Management
- MRHIF RFP – Reinsurance
- Aetna – New York Presbyterian Health System
- Express – Scripts

TOWN VISITS/MEETINGS/PLAN CHANGE REQUESTS

Our office frequently works with towns for review of plan options for union negotiations. If anyone is entering union negotiations and needs assistance, please feel free to contact our office directly to discuss.

ENROLLMENT, ELIGIBILITY, BILLING

The funds policy is to limit retro corrections, including terminations to 60 days. Please check your monthly invoice for accuracy. If you find a discrepancy, please report it immediately to the NJHIF enrollment Team at northernnjenrollments@permainc.com

- *Use of the WEX (formerly Benefits Express) enrollment system is mandatory.*

Online Enrollment System Training Schedule - 2024

PERMA offers virtual training and a refresher class of the online enrollment system the third Wednesday of each month. The session provides an overview of the Fund's enrollment system and shows HR users how to perform tasks in the system. To gain access to the Fund's enrollment system, each HR user must complete a system access form.

Wednesday -	April 17th 10:00 am - 11:00 am
Wednesday -	May 15th 10:00 am - 11:00 am
Wednesday -	June 19th 10:00 am - 11:00 am
Wednesday -	July 17th 10:00 am - 11:00 am
Wednesday -	August 21st 10:00 am - 11:00 am
Wednesday -	September 18th 10:00 am - 11:00 am
Wednesday -	October 16th 10:00 am - 11:00 am
Wednesday -	November 20th 10:00 am - 11:00 am

Please email Austin Flinn at PERMA to join a training session.

In the subject line of the email, please include *Training - Fund Name and Client Name*. Please be sure to add the date of the training you would like to attend to your email so an invite can be sent.

- **Email:** aflinn@permainc.com

NEW MEDICAL MEMBER SUBMISSIONS

The Twp of Mount Olive was successfully transitioned to the NJHIF effective 3/1/2024. This now completes the transition of 8 municipal groups who have transitioned from the SHBP to the NJMEBF since 1/1/2023. Just as a recap - the 8 new groups and effective dates are as follows:

Jefferson Twp - January 1, 2023
Madison Borough - April 1, 2023

Madison Housing Authority – May 1, 2023
Town of Boonton – May 1, 2023
Chatham Borough – August 1, 2023
Vernon Twp – September 1, 2023
Kinnelon Borough – October 1, 2023
Mount Olive Twp – March 1, 2024

DATA MANAGEMENT

Our office / data analyst has provided the data necessary for the actuary to complete the IBNR projections for the NJHIF.

MRHIF REINSURANCE RFP

Last year's RFP for the MRHIF contract was awarded as a single year contract since a multiyear contract, as has been the terms in the past, would need prior approval of the OSC which, according to our QPA wasn't feasible due to time constraints last year. So that we would be able to issue a multiyear award, we requested and received authorization to start the RFP process early this year in conjunction with our QPA by sending the required documents to OSC to obtain the required pre-approval which would put us on course to issue the formal RFP mid-year.

AETNA

New York Presbyterian Healthcare System – Possible Termination

Our office has been notified of the possible termination of New York Presbyterian Healthcare System.

There are 10 NJHIF members that have accessed the healthcare system within the last 12 months and may be affected by the termination. Attached separately is a copy of the notification letter Aetna has sent to any affected member.

Below is a list of Facilities that would be affected by the termination.

Columbia University Irving Medical Center
NewYork - Presbyterian Allen Hospital
NewYork - Presbyterian Westchester
NewYork - Presbyterian Morgan Stanley Children's Hospital
Weill Cornell Medical Center
NewYork - Presbyterian Lower Manhattan Hospital

NewYork - Presbyterian Westchester Division
NewYork - Presbyterian Brooklyn Methodist Hospital
NewYork - Presbyterian Queens
NewYork - Presbyterian Hudson Valley Hospital
Gracie Square Hospital

On 2/26/2024, NewYork-Presbyterian (NYP) Healthcare System sent notices to impacted members by email and/or mail advising them of the negotiation and potential termination. NYP has also created the following site to provide information for members: <https://www.nyp.org/aetna>. You can access a copy of NYP's letter from the site.

Aetna continues to negotiate with NewYork-Presbyterian Healthcare System in good faith, but the parties remain far apart. Aetna will provide an update on the negotiations with the facility during our fund meeting.

EXPRESS - SCRIPTS

SAVEON SP

The NJMEBF has saved a total of \$406,236 through the SAVEON SP Program for the 2023 calendar year with a total of 74 plan participants enrolled in the program. Drugs for the treatment of Inflammatory conditions continues to be the top expense for specialty in this program. The full SaveOn report is attached separately and provides additional information on other specialty medications and the savings associated with each.

Emerging Therapeutics: DrugWatch

January 2024

Pipeline Drugs: A Closer Look

In each issue of DrugWatch, the Emerging Therapeutics Department highlights one traditional and one specialty pipeline product with near-term approval expected.

Traditional Pipeline	
Drug: atropine 0.01% low dose	Action Date: Jan. 31, 2024
Manufacturer: Vyluma	Route: Ophthalmic
Indication: Myopia	
Comments:	
Vyluma is developing NVK-002, a low-dose atropine 0.01% formulation, to treat myopia (nearsightedness) in children 3 to 17 years of age. Studies have shown that atropine has the potential to reduce the progression of myopia by up to 60%. Pediatric myopia, which can start as early as 3 to 4 years of age, is a progressive condition that significantly impacts quality of life and increases the risk of other eye conditions, such as glaucoma, retinal detachment, and maculopathy. Myopia affects approximately 30% of the population. There are currently no FDA approved drugs for treating myopia. An approval decision for this product is expected by Jan. 31, 2024.	
Specialty Pipeline	
Drug: resmetirom	Action Date: Mar. 14, 2024
Manufacturer: Madrigal	Route: Oral
Indication: Nonalcoholic steatohepatitis (NASH)	
Comments:	
Madrigal Pharmaceuticals' resmetirom is a selective thyroid hormone receptor- β agonist that is pending approval for the treatment of patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis. NASH is also known as metabolic dysfunction-associated steatohepatitis (MASH). There are approximately 800,000 patients in the U.S. with NASH with advanced fibrosis (without cirrhosis) who are under the care of a hepatologist or gastroenterologist. In patients with NASH, liver fat and inflammation leads to liver damage and potentially liver cancer. Resmetirom is expected to be the first drug approved for NASH. It is an oral medication that is taken once daily. Approval is expected by Mar. 14, 2024.	

FDA Action Dates

Products in the table below are currently under FDA review with near-term FDA action dates.

Drug	Manufacturer	Use	S	Action Date
Egrifta (tesamorelin)*	Theratechnologies	HIV Lipodystrophy	S	Jan-22
Lumisight (pegulicanine)	Lumicell	Breast Cancer	S	Jan-22
Zynrelef (bupivacaine/meloxicam)*	Heron	Post-operative Pain		Jan-23
Yutrepia (treprostinil)	Liquidia Technologies	PAH	S	Jan-24
scopolamine nasal gel	Repurposed/Defender	Motion Sickness		Jan-26
atropine 0.01% low dose	Vyluma	Myopia		Jan-31
Dupixent (dupilumab)*	Regeneron/Sanofi	Eosinophilic Esophagitis	S	Jan-31
Onivyde (liposomal irinotecan)*	Ipsen	mPDAC	S	Feb-13
cefepime/taniborbactam	Venatorx	Urinary Tract Infection		Feb-22
lifileucel	Iovance	Melanoma	S	Feb-24
roluperidone	Minerva	Schizophrenia		Feb-26
Jaypicra (pirtobrutinib)*	Lilly	CLL	S	Feb. 2024
clobetasol 0.05% Susp.	Formosa /AimMax	Ocular Inflammation		Mar-04
glatiramer acetate, long-acting)	Mapi Pharma/Viatris	Multiple Sclerosis	S	Mar-08
Wegovy (semaglutide)*	Novo Nordisk	Heart Disease		Mar-11
Livmarli (maralixibat)*	Mirum	PFIC	S	Mar-13
resmetirom	Madrigal	NASH	S	Mar-14
Libmeldy (atidarsagene autotemcel)	Orchard Therapeutics	Metachromatic Leukodystrophy	S	Mar-18
aprocitan	J&J/Idorsia	Hypertension		Mar-19
givinostat	Italfarmaco	DMD	S	Mar-21
Hetlioz (tasimelteon)*	Vanda	Insomnia	S	Mar-24
sotatercept	Merck	PAH	S	Mar-26
Vafseo (vadadustat)	Otsuka/Akebia	Anemia	S	Mar-27
odronextamab	Regeneron	NHL	S	Mar-31
marnetegrane autotemcel	Rocket	Leukocyte Adhesion Deficiency	S	Mar-31
donanemab	Lilly	Alzheimer's Disease	S	1Q2024
Eohilia (budesonide oral susp.)	Takeda/Shire	Eosinophilic Esophagitis		1Q2024
Xolair (omalizumab)*	Genentech/Novartis	Food Allergies	S	1Q2024

* = New Indication; "S" = Specialty

AMD=Age-Related Macular Degeneration; CLL=Chronic Lymphocytic Leukemia;
DMD=Duchenne Muscular Dystrophy; PFIC=Familial Intrahepatic Cholestasis;
mPDAC=Metastatic Pancreatic Ductal Adenocarcinoma; NASH= Nonalcoholic Steatohepatitis;
NHL=Non-Hodgkin's Lymphoma; PAH=Pulmonary Arterial Hypertension

Emerging Therapeutics: DrugWatch

January 2024

FDA Updates

Recent New Drug Approvals

Date	Drug	Manufacturer	Use	S
Jan. 08	Zelsuvmi (berdazimer gel)	Novan/Ligand	Molluscum Contagiosum	

"S" = Specialty

Recent Generic Launches

Date	Drug	Manufacturer	Use	Annual Sales [^]
Dec. 14	Nascobal	Par	Anemia	\$77

[^] = Million

Patent Expirations: 2024

In 2024, around \$12 billion worth of first-time generics may be released. The table below shows the products losing patent protection in 2024. As always, availability of generic is subject to final FDA approval.

Drug	Manufacturer	Use	Patent Expiration	Annual Sales [^]
Gralise	Depomed	Nerve Pain	Jan. 01	\$100
Tasigna	Novartis	Cancer	Jan. 05	\$1,166
Emflaza	PTC Therapeutics	Muscular Dystrophies	Feb. 09	\$214
Radicava (IV)	Mitsubishi	Muscular Dystrophies	May. 05	\$329
Duavee	Pfizer	Hormonal Supplementation	May. 06	\$16
Saxenda	Novo Nordisk	Weight Loss	May. 12	\$1,135
Victoza	Novo Nordisk	Diabetes, Type 2	Jun. 22	\$3,677
Slynd	Exeltis	Contraceptives	Aug. 21	\$166
Sprycel	Bristol-Myers Squibb	Cancer	Sept. 2024	\$2,296
Sustol	Heron	Nausea/Vomiting	Sep. 28	\$16
Prialt	Elan	Pain	Oct. 01	\$28
Qsymia	Actavis	Weight Loss	Dec. 01	\$42
Byetta	AstraZeneca	Diabetes, Type 2	2024	\$62
Flovent HFA	GlaxoSmithKline	Asthma	2024	\$1,875
Folotyn	Allos	Cancer	2024	\$36
Gadavist	Bayer	Diagnostic Aids	2024	\$455
Gattex	Shire	Short Bowel Syndrome	2024	\$170
Isentress 400mg	Merck	HIV	2024	\$324
Ixempra	R-Pharm	Cancer	2024	\$14
Neupro Patch	UCB Pharma	Parkinson's Disease	2024	\$142
Rayos	Horizon Pharma	Inflammation	2024	\$120
Teflaro	Allergan	Infections	2024	\$171
Ventavis	Actelion	Pulmonary Hypertension	2024	\$10

[^] Millions (IQVIA sales [2022]); * = Settlement Agreement; Pending = Generic approved but launch is pending

"Generic" = Generic available; (AG) = Authorized product only

"Expired" = no active patents or exclusivities listed in FDA's Orange Book.

IPF = Idiopathic Pulmonary Fibrosis

Emerging Therapeutics: DrugWatch

February 2024

Pipeline Drugs: A Closer Look

In each issue of DrugWatch, the Emerging Therapeutics Department highlights one traditional and one specialty pipeline product with near-term approval expected.

Traditional Pipeline	
Drug: aprocitentan	Action Date: Mar. 19, 2024
Manufacturer: Janssen/Idorsia	Route: Oral
Indication: Resistant hypertension	
Comments: Janssen and Idorsia are developing aprocitentan, a dual endothelin receptor antagonist for treating adults with difficult to treat, or resistant hypertension. About 116 million adults in the U.S. have hypertension (high blood pressure), which if left untreated can increase the risk of heart attack, stroke, and chronic kidney disease. Most patients can control their blood pressure with lifestyle changes and medication, but about 10% have resistant hypertension, where blood pressure remains high despite treatment. If approved, aprocitentan will offer a unique treatment option to help treat patients with resistant hypertension. Following a previous FDA delay, the drug's approval decision is expected by March 19, 2024.	
Specialty Pipeline	
Drug: sotatercept	Action Date: Mar. 26, 2024
Manufacturer: Merck	Route: Subcutaneous (SC)
Indication: Pulmonary arterial hypertension (PAH)	
Comments: Merck's sotatercept is a fusion protein based on the activin receptor type IIA (ActRIIA) that is pending approval for the treatment of pulmonary arterial hypertension (PAH). Approximately 50,000 Americans have PAH, which is caused by constricted arteries in the lungs. Patients can experience shortness of breath, dizziness, chest pain, coughing, fatigue, and swelling of the feet and legs. Several drugs that dilate blood vessels are available to treat PAH; they are oftentimes used in combination. Sotatercept has a new mechanism and has demonstrated effectiveness when added onto a patient's current drug regimen. It is administered as a SC injection once every three weeks. Approval is expected by Mar. 26, 2024.	

FDA Action Dates

Products in the table below are currently under FDA review with near-term FDA action dates.

Drug	Manufacturer	Use	S	Action Date
Simlandi (adalimumab biosimilar)	Teva /Alvotech	Inflammatory Conditions	S	Feb-24
roluperidone	Minerva	Schizophrenia		Feb-26
Soliris Biosimilar	Amgen/Daiichi Sankyo	PNH	S	Feb-28
clobetasol 0.05% susp.	Formosa/AimMax	Ocular Inflammation		Mar-04
Hetlioz (tasimelteon)	Vanda	Insomnia	S	Mar-04
GA Depot 40mg	Mapi/Viatris	Multiple Sclerosis	S	Mar-08
Wegovy (semaglutide)*	Novo Nordisk	Heart Disease		Mar-09
Prauent (alirocumab)*	Regeneron	HeFH	S	Mar-10
Livmarli (maralixibat)*	Mirum	FIC	S	Mar-13
resmetirom	Madrigal	NASH	S	Mar-14
Breyanzi (lisocabtagene maraleucel)*	Bristol Myers Squibb	CLL/SLL	S	Mar-14
Xhance (fluticasone propionate)*	OptiNose	Chronic Sinusitis		Mar-16
Libmeldy (atidarsagene autotemcel)	Orchard	Metachromatic Leukodystrophy	S	Mar-18
aprocitentan	Janssen/Idorsia	Hypertension		Mar-19
givinostat	Italfarmaco	DMD	S	Mar-21
sotatercept	Merck	PAH	S	Mar-26
Vafseo (vadadustat)	Otsuka/Akebia	Anemia	S	Mar-27
Opsynvi (macitentan/tadalafil)	Janssen	PAH	S	Mar-30
odronextamab	Regeneron	NHL	S	Mar-31
Nexletol (bempedoic acid)*	Esperion	Hyperlipidemia		Mar-31
Brukina (zanubrutinib)*	BeiGene	Follicular Lymphoma	S	1Q:2024
clobetasol 0.05% nanoemulsion	Laboratorios Salvat	Ocular Inflammation		1Q:2024
clotrimazole otic	Laboratorios Salvat	Fungal Otitis Externa		1Q:2024
donanemab	Lilly	Alzheimer's Disease	S	1Q:2024
FluMist Quadrivalent*	AstraZeneca	Flu Vaccine		1Q:2024
Ixinity (trenonacog alfa)*	Medexus	Hemophilia B		1Q:2024
Jesduvroq (daprodustat)*	GlaxoSmithKline	Anemia	S	1Q:2024
deuruxolitinib	Sun Pharmaceuticals	Alopecia Areata	S	Mar-Apr

* = New Indication; "S" = Specialty

CLL=Chronic Lymphocytic Leukemia; DMD=Duchenne Muscular Dystrophy;
FIC=Familial Intrahepatic Cholestasis; HeFH=Heterozygous Familial Hypercholesterolemia;
NASH= Nonalcoholic Steatohepatitis; NHL=Non-Hodgkin's Lymphoma;
PAH=Pulmonary Arterial Hypertension; PNH=Paroxysmal Nocturnal Hemoglobinuria;
SLL=Small Lymphocytic Lymphoma

© Express Scripts Strategic Development, Inc. All Rights Reserved.

This document is proprietary and confidential to Express Scripts Strategic Development, Inc.
Unauthorized use and distribution are prohibited.

Emerging Therapeutics: DrugWatch

February 2024

FDA Updates

Recent New Drug Approvals

Date	Drug	Manufacturer	Use	S
Feb. 09	Eohilia (budesonide susp.)	Takeda/Shire	Eosinophilic Esophagitis	
Feb. 15	Aurlumyn (iloprost)	Civi Biopharma	Frostbite	
Feb. 16	Amtagvi (lifileucel)	Iovance	Melanoma	S

"S" = Specialty

Recent Generic Launches

Date	Drug	Manufacturer	Use	Annual Sales [^]
Jan. 05	Alrex	Bausch & Lomb	Ophthalmic Anti-Allergic	\$45
Jan. 10	FML	Allergan	Ophthalmic Anti-Inflammatory	\$62
Jan. 29	Gralise	Depomed	Pain/Inflammation	\$100
Feb. 23	Emflaza	PTC Therapeutics	Muscular Dystrophies	\$214

[^] = Million

Patent Expirations: 2024

In 2024, around \$12 billion worth of first-time generics may be released. The table below shows the products losing patent protection in 2024. As always, availability of generic is subject to final FDA approval.

Drug	Manufacturer	Use	Patent Expiration	Annual Sales [^]
Alrex	Bausch & Lomb	Ophth. Anti-Allergic	Generic	\$45
FML	Allergan	Ophth. Anti-Inflammatory	Generic	\$62
Gralise	Depomed	Nerve Pain	Generic	\$100
Emflaza	PTC Therapeutics	Muscular Dystrophies	Generic	\$214
Radicava (IV)	Mitsubishi	Muscular Dystrophies	May. 05	\$329
Duavee	Pfizer	Hormonal Supplementation	May. 06	\$16
Saxenda	Novo Nordisk	Weight Loss	Jun. 22	\$1,135
Victoza	Novo Nordisk	Diabetes, Type 2	Jun. 22	\$3,677
Tasigna	Novartis	Cancer	H1:2024	\$1,166
Slynd	Exeltis	Contraceptives	Aug. 21	\$166
Sprycel	Bristol-Myers Squibb	Cancer	Sept. 2024	\$2,296
Sustol	Heron	Nausea/Vomiting	Sep. 28	\$16
Prialt	Elan	Pain	Oct. 01	\$28
Qsymia	Actavis	Weight Loss	Dec. 01	\$42
Byetta	AstraZeneca	Diabetes, Type 2	2024	\$62
Flovent HFA	GlaxoSmithKline	Asthma	2024	\$1,875
Folotyn	Allos	Cancer	2024	\$36
Gadavist	Bayer	Diagnostic Aids	2024	\$455
Gattex	Shire	Short Bowel Syndrome	2024	\$170
Isentress 400mg	Merck	HIV	2024	\$324
Ixempra	R-Pharm	Cancer	2024	\$14
Neupro Patch	UCB Pharma	Parkinson's Disease	2024	\$142
Rayos	Horizon Pharma	Inflammation	2024	\$120
Teflaro	Allergan	Infections	2024	\$171
Ventavis	Actelion	Pulmonary Hypertension	2024	\$10

[^] Millions (IQVIA sales [2022]); * = Settlement Agreement; Pending = Generic approved but launch is pending

"Generic" = Generic available; (AG) = Authorized product only

"Expired" = no active patents or exclusivities listed in FDA's Orange Book.

IPF = Idiopathic Pulmonary Fibrosis



Aetna Health Inc.
P.O. Box 818089,
Cleveland, OH 44181-8089

<Insert MAILING Date>

ADDRESSEE
STREET ADDRESS
CITY, STATE, ZIP+4

NewYork-Presbyterian Healthcare System may be leaving our network

Our contract with NewYork-Presbyterian Healthcare System may end on **April 1, 2024**. This includes inpatient, outpatient, and clinic services. You can get care for covered services at these hospitals until that date. The plan's usual referral and prior authorization processes still apply.

The NewYork-Presbyterian Healthcare System facilities below are affected by this potential change:

Columbia University Irving Medical Center
NewYork-Presbyterian Allen Hospital
NewYork-Presbyterian Westchester
NewYork-Presbyterian Morgan Stanley Children's Hospital
Weill Cornell Medical Center
NewYork-Presbyterian Lower Manhattan Hospital
NewYork-Presbyterian Westchester Division
NewYork-Presbyterian Brooklyn Methodist Hospital
NewYork-Presbyterian Queens
NewYork-Presbyterian Hudson Valley Hospital
Gracie Square Hospital

Are you facing an emergency?

You can still use these hospitals, or **any** hospital, for an emergency. We'll cover the visit, even if the hospital isn't in our network.

Does your plan have out-of-network benefits?

If your plan allows you go to any hospital or provider outside the network, you can still use them after Click or tap to enter a date. for covered services. But you might pay more money out of your own pocket than you do now. You can save money by choosing someone in our network.

Will you have ongoing treatments after the end date?

If you are in an ongoing course of treatment, you have a right to continue that course of treatment for up to 90 days after the end date of April 1, 2024.

If you are pregnant, you may continue to receive care through delivery and any postpartum care directly related to the delivery.

For more information on transitional care coverage, call the number on your ID card.

What you should do: Choose a hospital who's in our network

To find a new network hospital or doctor, you can:

- Call Member Services at the number on your member ID card.
- Go to **Aetna.com** and click "Find a Doctor."
- Log in to your member website to make your search easier. (The website will give you pre-filled information.)

We're here to help

We are sorry for any issues this change may cause. If you have questions, just call the phone number on your ID card. You can also send us a secure email through the member log in tool on **Aetna.com**

Aetna is the brand name used for products and services provided by one or more of the Aetna group of companies, including Aetna Life Insurance Company and its affiliates (Aetna).

©2022 Aetna Inc.
00.32.586.1-NYV3 A
(03/21)

Aetna complies with applicable Federal civil rights laws and does not unlawfully discriminate, exclude or treat people differently based on their race, color, national origin, sex, age, or disability.

We provide free aids/services to people with disabilities and to people who need language assistance.

If you need a qualified interpreter, written information in other formats, translation or other services, call the number on your ID card.

If you believe we have failed to provide these services or otherwise discriminated based on a protected class noted above, you can also file a grievance with the Civil Rights Coordinator by contacting:

Civil Rights Coordinator,

P.O. Box 14462, Lexington, KY 40512 (CA HMO customers: PO Box 24030 Fresno, CA 93779), 1-800-648-7817, TTY: 711,

Fax: 859-425-3379 (CA HMO customers: 860-262-7705), CRCoordinator@aetna.com.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, or at 1-800-368-1019, 800-537-7697 (TDD)

FEBRUARY 2024

BE IT RESOLVED that the North Jersey Municipal Employee Benefit Fund's Executive Board,
hereby
authorizes the Fund treasurer to issue warrants in payment of the following claims; and

FUND YEAR 2023

Total Payments FY 2023	40.95
-------------------------------	--------------

FUND YEAR 202430

002793			
002793	EMPLOYEE BENEFITS CONSULTING	BROKER FEES 02/24	2,443.32
			2,443.32
002794			
002794	CORPORATE BENEFIT SOLUTIONS	BROKER FEES 02/24	2,277.88
			2,277.88
002795			
002795	SKYLANDS RISK MANAGEMENT	BROKER FEES 02/24	10,045.09
			10,045.09
002796			
002796	BROWN AND BROWN METRO LLC	BROKER FEES 02/24	6,834.73
			6,834.73
002797			
002797	CIVITAS NEW JERSEY, LLC	WELLNESS CONSULT SERVICES 02/24	2,083.33
			2,083.33
002798			
002798	VALLEY PHYSICIAN SERVICES PC	CORP WELLNESS WEBINAR PKG 2024	2,000.00
			2,000.00
002799			
002799	WORLD INSURANCE ASSOCIATES, LLC	BROKER FEES 02/24	1,258.07
			1,258.07
002800			
002800	ACRISURE, LLC	BROKER FEES 02/24	10,982.46
			10,982.46
002801			
002801	ACCESS	INV 10647860 DEP 421 12/31/23 FOR JAN	176.40
			176.40
002802			
002802	MUNICIPAL REINSURANCE H.I.F.	SPECIFIC REINSURANCE 02/24	343,526.82
			343,526.82
		Total Payments FY 2024	875,415.50
		TOTAL PAYMENTS ALL FUND YEARS	875,456.45

Chairperson

Attest:

Dated: _____

I hereby certify the availability of sufficient unencumbered funds in the proper accounts to fully pay the above claims.

Treasurer

NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND

BILLS LIST

MARCH 2024

WHEREAS, the Treasurer has certified that funding is available to pay the following bills:

BE IT RESOLVED that the North Jersey Municipal Employee Benefit Fund's Executive Board,
hereby
authorizes the Fund treasurer to issue warrants in payment of the following claims; and

FURTHER, that this authorization shall be made a permanent part of the records of the Fund.

FUND YEAR 2023

<u>CheckNumber</u>	<u>VendorName</u>	<u>Comment</u>	<u>InvoiceAmount</u>
002803			
002803	UNITED - MEDICARE ADVANTAGE	2023 ADJUSTMENT- UNDUE CREDIT.	326.00
			326.00
002804			
002804	LIFE LINE SCREENING	HEALTH SCREEN-PO 23-0913_PGK,1 9/23	4,250.00
002804	LIFE LINE SCREENING	HEALTH SCREEN -PO 23-0907_PGK,1 9/23	4,250.00
			8,500.00
		Total Payments FY 2023	8,826.00

FUND YEAR 2024

<u>CheckNumber</u>	<u>VendorName</u>	<u>Comment</u>	<u>InvoiceAmount</u>
002805			
002805	AETNA HEALTH MANAGEMENT, LLC	MEDICARE ADVANTAGE PREMIUM 03/24	235,497.54
			235,497.54
002806			
002806	UNITED - MEDICARE ADVANTAGE	MEDICARE ADVANTAGE PREM 03/24	48,502.48
			48,502.48
002807			
002807	DELTA DENTAL OF NEW JERSEY INC	DENTAL TPA 03/24	6,429.50
			6,429.50
002808			
002808	AETNA	MEDICAL TPA 03/24	73,544.40
			73,544.40
002809			
002809	PERMA	POSTAGE 02/24	188.67
002809	PERMA	ADMIN FEES 03/24	40,884.25
			41,072.92
002810			
002810	MICHAEL J. SOCCIO	TREASURER FEE 03/24	1,953.00
			1,953.00
002811			
002811	JOSEPH L. VOZZA AGENCY INC.	WELLNESS 03/24	3,056.25
002811	JOSEPH L. VOZZA AGENCY INC.	PROGRAM MANAGER FEES 03/24	47,486.24
002811	JOSEPH L. VOZZA AGENCY INC.	PRIOR PERIOD ADJUSTMENTS 03/24	-600.33
002811	JOSEPH L. VOZZA AGENCY INC.	BROKER FEES 03/24	30,368.78
			80,310.94
002812			
002812	DORSEY & SEMRAU	SPECIAL LITIGATION INV 21076 02/24	201.50
002812	DORSEY & SEMRAU	ATTORNEY RETAINER FEE 03/24	1,667.00
			1,868.50

002813			
002813	EMPLOYEE BENEFITS CONSULTING	BROKER FEES 03/24	2,365.44
			2,365.44
002814			
002814	CORPORATE BENEFIT SOLUTIONS	BROKER FEES 03/24	2,174.34
			2,174.34
002815			
002815	SKYLANDS RISK MANAGEMENT	BROKER FEES 03/24	9,941.71
			9,941.71
002816			
002816	BROWN AND BROWN METRO LLC	BROKER FEES 03/24	6,876.50
			6,876.50
002817			
002817	CIVITAS NEW JERSEY, LLC	WELLNESS CONSULT SERVICES 03/24	2,083.33
			2,083.33
002818			
002818	WORLD INSURANCE ASSOCIATES, LLC	BROKER FEES 03/24	1,263.69
			1,263.69
002819			
002819	ACRISURE, LLC	BROKER FEES 03/24	8,154.98
			8,154.98
002820			
002820	GANNETT NEW YORK NJ LOCALIQ	A # 1184295 INV 6239880- 9885722 2/27/24	66.96
			66.96
002821			
002821	ACCESS	INV 10700965 DEPT 421 1/31/24 FOR FEB	165.36
			165.36
002822			
002822	MUNICIPAL REINSURANCE H.I.F.	SPECIFIC REINSURANCE 03/24	339,565.92
			339,565.92
		Total Payments FY 2024	861,837.51
		TOTAL PAYMENTS ALL FUND YEARS	870,663.51

Chairperson

Attest:

Dated: _____

I hereby certify the availability of sufficient unencumbered funds in the proper accounts to fully pay the above claims.

Treasurer

North Jersey Municipal Employee Benefits Fund										
SUMMARY OF CASH TRANSACTIONS - ALL FUND YEARS COMBINED										
Current Fund Year: 2024										
Month Ending: January										
	Medical	Dental	Rx	Reinsurance	Dividend Reserve	LFC	Admin	0	0	TOTAL
OPEN BALANCE	11,898,328.07	206,413.96	335,696.86	(114,036.99)	2,768,454.67	0.00	(75,476.79)	0.00	0.00	15,019,379.78
RECEIPTS										
Assessments	2,886,604.39	87,536.94	45,744.97	120,741.43	0.00	0.00	106,882.09	0.00	0.00	3,247,509.82
Refunds	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Invest Pymnts	44,966.85	780.10	3,059.53	0.00	10,462.71	0.00	56.66	0.00	0.00	59,325.85
Invest Adj	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Subtotal Invest	44,966.85	780.10	3,059.53	0.00	10,462.71	0.00	56.66	0.00	0.00	59,325.85
Other *	597,975.10	432.08	63,445.00	0.00	0.00	0.00	127.50	0.00	0.00	661,979.67
TOTAL	3,529,546.34	88,749.12	112,249.50	120,741.43	10,462.71	0.00	107,066.25	0.00	0.00	3,968,815.34
EXPENSES										
Claims Transfers	4,432,662.53	143,102.17	393,099.20	0.00	0.00	0.00	0.00	0.00	0.00	4,968,863.90
Expenses	37,442.00	0.00	0.00	343,622.23	0.00	0.00	689,254.27	0.00	0.00	1,070,318.50
Other *	405,242.51	(62,507.56)	(84,670.90)	(136,610.26)	250,000.00	0.00	(99,534.42)	0.00	0.00	271,919.37
TOTAL	4,875,347.04	80,594.61	308,428.30	207,011.97	250,000.00	0.00	589,719.85	0.00	0.00	6,311,101.77
END BALANCE	10,552,527.37	214,568.47	139,518.06	(200,307.53)	2,528,917.38	0.00	(558,130.39)	0.00	0.00	12,677,093.35

CERTIFICATION AND RECONCILIATION OF CLAIMS PAYMENTS AND RECOVERIES									
North Jersey Municipal Employee Benefits Fund									
Month		January							
Current Fund Year		2024							
		1.	2.	3.	4.	5.	6.	7.	8.
Policy		Calc. Net	Monthly	Monthly	Calc. Net	TPA Net	Variance	Delinquent	Change
Year	Coverage	Paid Thru	Net Paid	Recoveries	Paid Thru	Paid Thru	To Be	Unreconciled	This
		Last Month	January	January	January	January	Reconciled	Variance From	Month
2024	Medical	0.00	1,515,218.40	0.00	1,515,218.40	0.00	1,515,218.40	0.00	1,515,218.40
	Dental	0.00	80,280.30	0.00	80,280.30	0.00	80,280.30	0.00	80,280.30
	Rx	0.00	236,257.18	0.00	236,257.18	0.00	236,257.18	0.00	236,257.18
	0	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Total	0.00	1,831,755.88	0.00	1,831,755.88	0.00	1,831,755.88	0.00	1,831,755.88

SUMMARY OF CASH AND INVESTMENT INSTRUMENTS						
North Jersey Municipal Employee Benefits Fund						
ALL FUND YEARS COMBINED						
CURRENT MONTH	January					
CURRENT FUND YEAR	2024					
Description:		CASH MANAGEMENT FUND	TD BANK ASSET MANAGEMENT	TD Bank Gift Card Account	Investors Bank	CITIZENS
ID Number:						
Maturity (Yrs)						
Purchase Yield:						
TOTAL for All Accts & instruments						
Opening Cash & Investment Balance	\$15,019,379.78	3,169,310.88	7,344,279.79	-	-	4,505,789.11
Opening Interest Accrual Balance	\$32,680.81	-	32,680.81	-	-	-
1	Interest Accrued and/or Interest Cost	-\$20.18	\$0.00	-\$20.18	\$0.00	\$0.00
2	Interest Accrued - discounted Instr.s	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
3	(Amortization and/or Interest Cost)	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
4	Accretion	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
5	Interest Paid - Cash Instr.s	\$59,325.85	\$14,361.09	\$32,684.20	\$0.00	\$12,280.56
6	Interest Paid - Term Instr.s	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
7	Realized Gain (Loss)	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
8	Net Investment Income	\$59,305.67	\$14,361.09	\$32,664.02	\$0.00	\$12,280.56
9	Deposits - Purchases	\$3,638,656.16	\$0.00	\$0.00	\$0.00	\$3,638,656.16
10	(Withdrawals - Sales)	-\$6,040,268.46	\$0.00	-\$1,086.04	\$0.00	-\$6,039,182.42
Ending Cash & Investment Balance	\$12,677,093.33	\$3,183,671.97	\$7,375,877.95	\$0.00	-\$2,388,245.70	\$4,505,789.11
Ending Interest Accrual Balance	\$32,660.63	\$0.00	\$32,660.63	\$0.00	\$0.00	\$0.00
Plus Outstanding Checks	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00	\$0.00
(Less Deposits in Transit)	-\$69,656.00	\$0.00	\$0.00	\$0.00	-\$69,656.00	\$0.00
Balance per Bank	\$12,607,437.33	\$3,183,671.97	\$7,375,877.95	\$0.00	-\$2,457,901.70	\$4,505,789.11

RESOLUTION NO. 24-16

**NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND
APPROVAL OF THE FEBRUARY AND MARCH 2024 BILLS LISTS**

WHEREAS, the North Jersey Municipal Employee Benefits Fund held a Public Meeting on **March 28, 2024** the purposes of conducting the official business of the Fund; and

WHEREAS, The Treasurer for the Fund presented bills lists to satisfy outstanding costs incurred for operating the Fund during the months February and March 2024 for consideration and approval of the Executive Committee; and

WHEREAS, The Treasurer for the Fund presented a Treasurers Report which detailed the claims payments and imprest transfers for the Fund for the Month of January for all Fund Years for consideration and approval of the Executive Committee; and

WHEREAS, a quorum of the Executive Committee was present thereby conforming with the By-laws of the Fund to conduct official business of the Fund,

NOW THEREFORE BE IT RESOLVED the Commissioners of the Executive Committee of the North Jersey Municipal Employee Benefits Fund hereby approve the Bills List for February and March 2024 prepared by the Treasurer of the Fund and duly authorize and concur said bills to be paid expeditiously, in accordance with the laws and regulations promulgated by the State of New Jersey for Municipal Health Insurance Funds.

NOW, THEREFORE BE IT FURTHER RESOLVED, the Commissioners of the Executive Committee of the North Jersey Municipal Employee Benefits Fund hereby approve the Treasurers Report as furnished by the Treasurer of the Fund and concur with actions undertaken by the Treasurer, in accordance with the laws and regulations promulgated by the State of New Jersey for Municipal Health Insurance Funds.

ADOPTED: March 28, 2024

BY: _____
CHAIRPERSON

ATTEST:

SECRETARY



TO: NJMEBF Executive Committee and Commissioners

FROM: Marianne Eskilson, VP Civitas NJ; Gateway-BMED Wellness Consultant

DATE: March 14, 2024

RE: Report of Activity and Progress

STATUS UPDATE

1. **Education:** Educational webinar schedules have been distributed to member agencies and participants are actively viewing on-demand webinars and attending live webinars. Feedback continues to be highly positive.
2. **Newsletter:** A renewal contract has been secured with the vendor who provides the newsletter for 2024, where pricing will remain at 2023 levels. The monthly newsletter continues to be sent to all local wellness program ambassadors monthly for distribution to their entire full-time employee population.
3. **Non-Participation Agencies:** It is our intention to make contact with the commission from each agency member to seek guidance, particularly from non-participating fund agencies, as to whom they would like monthly links to educational programming and newsletters to be sent so that they can be distributed to their full-time employee population. The newsletter is available in both an interactive digital version, as well as a static pdf. Our office creates a specialized article for the Fund that can be found on the right-hand column of the first page of each edition.
4. **Wrapping Up 2023 and Ramping Up into 2024:**
 - a. **Aggregate Sleep Assessment Report:** 2023 was the first year the Fund has included a component that focuses on sleep. The results of the aggregate report provided by the vendor, which is provided to you under separate cover) indicates that amongst the three agencies evaluated there was a high percentage of risk associated with the participant's quality of sleep. Risks noted could be the result of factors including sleep hygiene, diet, exercise and/or other factors. Equipping participants with personalized information about warning signs or the potential need to adapt their sleep routines, dietary or fitness lifestyles in order to improve

their sleep is a great benefit to those who participated. Impacts of sleep on overall health continues to be a hot topic of research in scientific circles.

b. Local Program Kickoffs: All participating agencies have initiated their programs and are working with us to schedule their 2024 Fund sponsored components.

5. Eye Towards Data and Information Transfer to New Wellness Coordinator: Now that the 2024 program is up and running, our priority focus is on putting together a comprehensive package of documents and files for the new wellness coordinator's use, once the "baton" has been passed on May 1 2024.



Executive Summary

Sleep Screening and Sleep Hygiene 1-on-1



Table Of Content

- Program Goals and Specifications
- Participation and Course Components
 - Day of Intervention:
 - Participation
- Program Outcomes
 - Risk Identification
 - Referrals
- Thank You and Contact Information

Executive Summary

The following document will summarize service provided in 2023 through the *Sleep Screening and Sleep Hygiene 1-on-1* program.



Program Goals and Specifications

It is well documented in the scientific literature that employees suffering from sleep related disorders are more likely to display increased productivity loss, higher rates of absenteeism, and are at a higher risk of catastrophic claims due to life-threatening diseases attributed to poor quality or lack of quantity of sleep. Therefore, the *primary goal of the Atlantic Health System (AHS), Atlantic Corporate Health (ACH) Sleep Screening and Sleep Hygiene 1-on-1 (SS&SH) Program is to identify and provide medical referrals to the high risk and, when medically indicated, the marginal/escalating risk populations.* Secondary program goals include:

1. Increasing healthy sleep knowledge for all program participants.
2. Providing individualized sleep plans for high to moderate risk participants.

From June 21st to November 14th, 2023 AHS provided the abovementioned program to employees in Hardyston Township, Randolph Township and Sparta Township. The majority of sessions occurred in person but some participants had virtual appointments due to work schedules.

Participation and Course Components – Day of Intervention

Participation: 154

Township Intervention (day of) included a Sleep Screening with AHS Polysomnographic Technologist, a Sleep Hygiene Consult with one of two AHS health coaches/CHES present at the employer-site. These sessions also included medical referrals and a sleep plan when indicated.



Program Outcomes

Quick Look

- Identification of High-Risk Population: 22
- Identification of Rising-Risk Population: 33
- Total Referrals: 56


Eligible participants could receive a referral to a Sleep Center and/or Wellness Referrals. Wellness Referrals are defined as Nutrition, Fitness, or "Other." In this case, the "Other Referral" was for an ENT Specialist.



Program Outcomes

Participants were placed into one of three risk categories:

- **No Risk to Minimal**- No sleep disturbances assessed. No to minimal healthy lifestyle behavior changes recommended. Individual may be having acute sleep disturbance, but screening does not indicate the need for medical intervention.
- **Marginal and Escalating Risk (aka Rising Risk)**- Persistent acute sleep disturbance with increased need for healthy lifestyle behavior change.
- **High Risk**- Sleep assessment results indicate need for medical intervention with or without healthy lifestyle behavior needs.



Thank You and Contact Information

We are grateful to have provided services through the North Jersey Municipal Employee Benefits Fund, over the last few months. Our partnership is important to us and it is our hope that your wellness initiative has been supported effectively. Again, thank you for partnering with Atlantic Health System, Atlantic Corporate Health.



**NORTH JERSEY MUNICIPAL
EMPLOYEE BENEFITS FUND**

Monthly Claim Activity Report

March 28, 2024



NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND

	MEDICAL CLAIMS PAID 2022	# OF EES	PER EE	MEDICAL CLAIMS PAID 2023	# OF EES	PER EE
JANUARY	\$2,046,453	1,357	\$ 1,508	\$2,295,816	1,496	\$ 1,535
FEBRUARY	\$2,000,969	1,357	\$ 1,475	\$2,276,872	1,502	\$ 1,516
MARCH	\$2,490,470	1,363	\$ 1,827	\$2,379,988	1,503	\$ 1,583
APRIL	\$1,875,739	1,370	\$ 1,369	\$2,612,511	1,605	\$ 1,628
MAY	\$2,619,507	1,364	\$ 1,920	\$3,090,950	1,668	\$ 1,853
JUNE	\$2,316,285	1,360	\$ 1,703	\$3,170,703	1,662	\$ 1,908
JULY	\$2,116,211	1,354	\$ 1,563	\$2,465,662	1,669	\$ 1,477
AUGUST	\$2,519,012	1,352	\$ 1,863	\$3,717,731	1,719	\$ 2,163
SEPTEMBER	\$2,017,188	1,353	\$ 1,491	\$2,976,764	1,836	\$ 1,621
OCTOBER	\$2,151,983	1,353	\$ 1,591	\$3,092,101	1,865	\$ 1,658
NOVEMBER	\$2,365,176	1,357	\$ 1,743	\$2,906,862	1,866	\$ 1,558
DECEMBER	\$2,206,152	1,345	\$ 1,640	\$3,142,985	1,880	\$ 1,672
TOTALS	\$26,725,146			\$34,128,946		
				2023 Average	1,689	\$1,681
				2022 Average	1,357	\$1,641



NORTH JERSEY MUNICIPAL EMPLOYEE BENEFITS FUND

	MEDICAL CLAIMS PAID 2023	# OF EES	PER EE	MEDICAL CLAIMS PAID 2024	# OF EES	PER EE
JANUARY	\$2,295,816	1,496	\$ 1,535	\$3,931,217	1,920	\$ 2,048
FEBRUARY	\$2,276,872	1,502	\$ 1,516			
MARCH	\$2,379,988	1,503	\$ 1,583			
APRIL	\$2,612,511	1,605	\$ 1,628			
MAY	\$3,090,950	1,668	\$ 1,853			
JUNE	\$3,170,703	1,662	\$ 1,908			
JULY	\$2,465,662	1,669	\$ 1,477			
AUGUST	\$3,717,731	1,719	\$ 2,163			
SEPTEMBER	\$2,976,764	1,836	\$ 1,621			
OCTOBER	\$3,092,101	1,865	\$ 1,658			
NOVEMBER	\$2,906,862	1,866	\$ 1,558			
DECEMBER	\$3,142,985	1,880	\$ 1,672			
TOTALS	\$34,128,946			\$3,931,217		
				2024 Average	1,920	\$2,048
				2023 Average	1,689	\$1,681

Large Claimant Report (Drilldown) - Claims Over \$100000

Plan Sponsor Unique ID : All
Customer: North Jersey Municipal Employee Benefits Fund
Group / Control: 00727848,00866355,SI220763

Paid Dates: 12/01/2023 - 12/31/2023
Service Dates: 01/01/2011 - 12/31/2023
Line of Business: All

	Paid Amt
	\$165,271.40
	\$140,145.71
	\$120,376.44
Total:	\$425,793.55

Large Claimant Report (Drilldown) - Claims Over \$100000

Plan Sponsor Unique ID : All
Customer: North Jersey Municipal Employee Benefits Fund
Group / Control: 00727848,00866355,SI220763

Paid Dates: 01/01/2024 - 01/31/2024
Service Dates: 01/01/2011 - 01/31/2024
Line of Business: All

	Paid Amt
	\$224,463.35
	\$108,295.84
Total:	\$332,759.19

**Medical Claims Paid:
January 2024- January 2024**Total Medical Paid per EE: **\$2,048****Network Discounts**

Inpatient: **66.3%**
Ambulatory: **68.7%**
Physician/Other: **67.8%**
TOTAL: 67.8%

Provider Network

% Admissions In-Network: **96.7%**
% Physician Office: **91.6%**

Aetna Book of Business:
Admissions 98.5%; Physician 90.9%

**Top Facilities Utilized (by total
Medical Spend)**

- Morristown Medical Center
- Chilton Medical Center
- Hackensack University Medical
- Cooperman Barnabas Medical
- Newton Medical Center

**Catastrophic Claim Impact
January 2024- January 2024**

Number of Claims Over \$50,000: **10**
Claimants per 1000 members: **2.0**
Avg. Paid per Claimant: **\$86,610**
Percent of Total Paid: **24.1%**
• Aetna BOB- HCC account for an
average of 43.2% of total Medical Cost

**Aetna One Flex Member Outreach:
thru January 2024**

Total Members Identified: **1,025**
Members Targeted for 1:1 Nurse
Support : **201**
Members Targeted for digital activity:
824
Member 1:1 outreach completed:
190
Member 1:1 Outreach in Progress: **11**

**Teladoc Activity:
January 2024 thru January 2024**

Total Registrations: **3**
Total Online Visits: **22**
Total Net Claims Savings: **\$10,403**
Total Visits w/ Rx: **7**

Mental Health Visits: **2**
Dermatology Visits: **0**

**Service Center Performance Goal
Metrics YTD 2024****Customer Service Performance**

1st Call Resolution: **93.9%**
Abandonment Rate: **0.57%**
Avg. Speed of Answer: **17.1 sec**

Claims PerformanceFinancial Accuracy: **98.25%**

90% processed w/in: **7.9 days**
95% processed w/in: **14.0 days**

Claims Performance (Monthly)

(February 2024)

90% processed w/in: **7.9 days**
95% processed w/in: **12.3 days**
(Note: This is not a PG metric)

Performance Goals

1st Call Resolution: **90%**
Abandonment Rate less than: **3.0%**
Average Speed of Answer: **30 sec**

Financial Accuracy: **99%****Turnaround Time**

90% processed w/in: **14 days**
95% processed w/in: **30 days**



EXPRESS SCRIPTS®

North Jersey Municipal Employee Benefits Fund - Monthly Utilization Tracking Report

Total Component/Date of Service (Month)	2023 01	2023 02	2023 03	2023 Q1	2023 04	2023 05	2023 06	2023 Q2	2023 07	2023 08	2023 09	2023 Q3	2023 10	2023 11	2023 12	2023 Q4	2023 YTD
Membership	3,873	3,863	3,887	3,874	4,143	4,320	4,331	4,265	4,342	4,485	4,817	4,548	4,889	4,905	4,919	4,904	4,398
Total Days	153,428	137,350	155,285	446,063	150,154	171,679	168,062	489,895	167,616	182,884	176,070	526,570	193,309	185,217	190,970	569,496	2,032,024
Total Patients	1,550	1,471	1,557	2,318	1,557	1,713	1,694	2,577	1,661	1,720	1,812	2,735	2,001	1,918	2,032	3,017	3,942
Total Plan Cost	\$548,171	\$576,692	\$662,404	\$1,787,268	\$584,221	\$747,892	\$850,782	\$2,182,895	\$810,505	\$893,758	\$835,235	\$2,539,498	\$906,849	\$927,451	\$976,059	\$2,810,359	\$9,320,019
Generic Fill Rate (GFR) - Total	83.3%	84.4%	84.9%	84.2%	85.6%	86.8%	85.0%	85.8%	85.2%	85.5%	83.4%	84.7%	81.7%	84.7%	86.4%	84.3%	84.7%
Plan Cost PMPM	\$141.54	\$149.29	\$170.42	\$153.77	\$141.01	\$173.12	\$196.44	\$170.62	\$186.67	\$199.28	\$173.39	\$186.13	\$185.49	\$189.08	\$198.43	\$191.01	\$176.60
Total Specialty Plan Cost	\$192,512	\$223,063	\$248,701	\$664,276	\$205,135	\$301,686	\$387,694	\$894,515	\$354,876	\$383,566	\$325,876	\$1,064,318	\$352,165	\$397,833	\$435,410	\$1,185,408	\$3,808,517
Specialty % of Total Specialty Plan Cost	35.1%	38.7%	37.5%	37.2%	35.1%	40.3%	45.6%	41.0%	43.8%	42.9%	39.0%	41.9%	38.8%	42.9%	44.6%	42.2%	40.9%

Total Component/Date of Service (Month)	2024 01	2024 02	2024 03	2024 Q1	2024 04	2024 05	2024 06	2024 Q2	2024 07	2024 08	2024 09	2024 Q3	2024 10	2024 11	2024 12	2024 Q4	2024 YTD
Membership	4,905																
Total Days	202,941																
Total Patients	1,967																
Total Plan Cost	\$865,104																
Generic Fill Rate (GFR) - Total	86.0%																
Plan Cost PMPM	\$176.37																
% Change Plan Cost PMPM	24.6%																
Total Specialty Plan Cost	\$308,439																
Specialty % of Total Specialty Plan Cost	35.7%																

2023 Plan Performance



Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2024 Evernorth Health Services.

Express Scripts
By EVERNORTH

1

Top Line Performance Metrics

North Jersey							
Description	2023	2022	Change				
Avg Subscribers per Month	1,758	1,426	23.3%				
Avg Members per Month	4,398	3,572	23.1%				
Number of Unique Patients	3,942	3,005	31.2%				
Pct Members Utilizing Benefit	89.6%	84.1%	5.5				
Total Plan Cost Net	\$5,990,444	\$4,630,688	29.4%				
Total Days	2,032,062	1,694,923	19.9%				
Total Adjusted Rxs	77,648	64,283	20.8%				
Average Member Age	37.2	37.5	-0.8%				
Plan Cost Net PMPM	\$113.51	\$108.03	5.1%	\$115.03	11.0%	\$132.31	7.7%
Plan Cost Net/Day	\$2.95	\$2.73	7.9%	\$2.74	7.7%	\$3.12	6.8%
Plan Cost Net per Adjusted Rx	\$77.15	\$72.04	7.1%	\$72.74	7.7%	\$82.37	7.5%
Nbr Adjusted Rxs PMPM	1.47	1.50	-1.9%	1.58	3.1%	1.61	0.2%
Generic Fill Rate	85.7%	85.6%	0.1	86.1%	0.3	86.9%	0.4
90 Day Utilization	65.4%	64.9%	0.5	67.3%	-0.5	63.8%	0.3
Retail - Maintenance 90 Utilization	36.1%	35.4%	0.7	30.3%	1.3	45.6%	0.5
Home Delivery Utilization	29.4%	29.6%	-0.2	37.0%	-1.8	18.3%	-0.2
Member Cost Net %	16.9%	23.4%	-6.6	17.1%	-1.1	12.8%	-0.1
Specialty Percent of Plan Cost Net	38.2%	50.9%	-12.7	42.3%	-0.9	58.1%	2.3
Specialty Plan Cost Net PMPM	\$43.37	\$54.95	-21.1%	\$48.70	8.7%	\$76.92	12.2%
Formulary Compliance Rate	98.0%	97.4%	0.7	97.8%	0.5	99.0%	0.2
Peer 1 = 'Coalition - Level Care LLC' market segment							
Peer 2 = 'Government - NFF Formulary' market segment							

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2024 Evernorth Health Services.

Key Statistics: Specialty Detailed

Description	North Jersey					
	Non-Specialty			Specialty		
	2023	2022	Change	2023	2022	Change
Avg Subscribers per Month	1,758	1,426	23.3%	1,758	1,426	23.3%
Avg Members per Month	4,398	3,572	23.1%	4,398	3,572	23.1%
Number of Unique Patients	3,938	3,004	31.1%	148	105	41.0%
Pct Members Utilizing Benefit	89.5%	84.1%	5.4	3.4%	2.9%	0.4
Total Plan Cost Net	\$3,701,702	\$2,275,405	62.7%	\$2,288,742	\$2,355,283	-2.8%
Percent of Total Plan Cost Net	61.8%	49.1%	12.7	38.2%	50.9%	-12.7
Total Days	2,005,162	1,670,243	20.1%	26,900	24,680	9.0%
Total Adjusted Rx	76,677	63,390	21.0%	971	893	8.7%
Percent of Total Adjusted Rx	98.75%	98.61%	0.1	1.25%	1.39%	-0.1
Plan Cost Net PMPM	\$70.14	\$53.08	32.1%	\$43.37	\$54.95	-21.1%
Plan Cost Net/Day	\$1.85	\$1.36	35.5%	\$85.08	\$95.43	-10.8%
Plan Cost Net per Adjusted Rx	\$48.28	\$35.90	34.5%	\$2,357.10	\$2,637.50	-10.6%
Nbr Adjusted Rx PMPM	1.45	1.48	-1.8%	0.02	0.02	-11.7%
Generic Fill Rate	86.5%	86.6%	-0.1	19.9%	16.5%	3.4
Member Cost Net %	8.5%	11.2%	-2.8	27.6%	32.4%	-4.8

Specialty Peer 1 = 'Coalition - Level Care LLC' market segment

Specialty Peer 2 = 'Government - NPF Formulary' market segment

Specialty Peer 1		Specialty Peer 2	
2023	Change	2023	Change
\$48.70	8.7%	\$76.92	12.2%
\$87.16	-2.9%	\$135.87	4.4%
\$2,380.79	-3.8%	\$3,842.56	4.1%
0.02	12.9%	0.02	7.7%
23.6%	2.3	21.5%	-0.3
24.3%	-1.1	6.9%	-0.4

Top 10 Indications

Top Indications by Plan Cost Net															
2023									2022						
		Indication	Adjusted		Plan Cost Net	Generic Fill Rate	Peer Generic Fill Rate	Plan Cost Net PMPM	Adjusted		Plan Cost Net	Generic Fill Rate	Plan Cost Net PMPM	Plan Cost Net	
Rank	Peer Rank		Rxs	Patients					Rxs	Patients				PMPM	% Change
1	1	INFLAMMATORY CONDITIONS	592	80	\$1,260,615	40.7%	51.1%	\$23.89	1	424	49	\$726,799	34.7%	\$16.96	40.9%
2	2	DIABETES	6,022	324	\$948,930	32.0%	36.3%	\$17.98	3	4,615	242	\$422,553	35.6%	\$9.86	82.4%
3	4	WEIGHT LOSS	486	101	\$374,532	10.7%	6.0%	\$7.10	21	123	26	\$65,934	22.0%	\$1.54	361.4%
4	5	MULTIPLE SCLEROSIS	58	6	\$247,660	13.8%	60.1%	\$4.69	6	52	6	\$166,712	17.3%	\$3.89	20.7%
5	12	MIGRAINE HEADACHES	547	98	\$214,220	42.0%	46.9%	\$4.06	14	356	63	\$96,299	53.7%	\$2.25	80.7%
6	3	CANCER	350	50	\$196,681	94.6%	80.7%	\$3.73	5	331	45	\$291,000	88.2%	\$6.79	-45.1%
7	6	SKIN CONDITIONS	849	484	\$195,950	87.4%	85.5%	\$3.71	11	628	369	\$117,332	88.9%	\$2.74	35.6%
8	7	ASTHMA	2,816	615	\$187,396	76.6%	76.1%	\$3.55	7	2,436	491	\$158,591	73.8%	\$3.70	-4.0%
9	69	CYSTIC FIBROSIS	20	3	\$170,451	30.0%	100.0%	\$3.23	4	48	3	\$386,878	14.6%	\$9.03	-64.2%
10	8	ANTICOAGULANT	581	77	\$155,608	20.1%	21.2%	\$2.95	8	557	64	\$139,985	14.9%	\$3.27	-9.7%
Total Top 10:			12,321		\$3,952,043	47.2%		\$74.88	9,570		\$2,572,082	49.7%	\$60.01	24.8%	
Differences Between Periods:			2,751		\$1,379,961	-2.5%		\$14.88							

The largest financially impactful change was in Inflammatory Conditions, driving \$0.5M in increased net cost for a 40.9% increase in Net PMPM

Weight Loss trend increased 361.4%, contributing an additional \$5.56 to Net PMPM

Represents 61.2% of your total Plan Cost Net

Peer = 'Coalition - Level Care LLC' market segment

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2024 Evernorth Health Services.

Express Scripts

By EVERNORTH

4

Top 25 Drugs

Top Drugs by Plan Cost Net																		
2023										2022							% Change	
Rank	Peer Rank	Brand Name	Indication	Adj. Ros	Pts.	Plan Cost Net	Peer Plan		Rank	Adj. Ros	Pts.	Plan Cost Net	Plan Cost Net PMPM	Plan Cost Net PMPM	Plan Cost Net PMPM	Peer Plan Cost Net PMPM		
							Cost Net	PMPM										
1	4	WEGOVY	WEIGHT LOSS	379	69	\$339,303	\$6.43	\$5.75	46	30	7	\$24,569	\$0.57	\$0.57	1021.6%	339.4%		
2	1	STELARA*	INFLAMMATORY CONDITIONS	96	7	\$317,073	\$6.01	\$2.95	2	51	6	\$228,931	\$5.34	\$2.95	12.5%	-16.5%		
3	2	OZEMPIC	DIABETES	478	63	\$229,346	\$4.35	\$4.04	7	229	29	\$89,549	\$2.09	\$2.09	108.0%	88.6%		
4	6	MONJARO	DIABETES	251	45	\$151,127	\$2.86	\$2.05	136	14	5	\$6,760	\$0.16	\$0.16	1715.7%	1373.6%		
5		TYVASO DPI*	PULMONARY HYPERTENSION	7	1	\$148,563	\$2.81											
6	33	ENBREL SURECLICK*	INFLAMMATORY CONDITIONS	39	5	\$138,439	\$2.62	\$0.83	16	20	3	\$48,727	\$1.14	\$0.83	130.8%	-1.3%		
7	36	HUMIRA(CF)*	INFLAMMATORY CONDITIONS	34	2	\$118,962	\$2.25	\$0.82	23	14	1	\$37,489	\$0.87	\$0.87	157.7%	109.2%		
8	17	SKYRZI PEN*	INFLAMMATORY CONDITIONS	31	3	\$116,729	\$2.21	\$1.24	29	6	3	\$31,678	\$0.74	\$0.74	199.3%	154.2%		
9		CABOMETYX*	CANCER	5	1	\$113,675	\$2.15											
10	3	HUMIRA(CF) PEN*	INFLAMMATORY CONDITIONS	34	6	\$111,921	\$2.12	\$3.29	6	41	4	\$108,019	\$2.52	\$2.52	-15.8%	1.7%		
11		KALYDECO*	CYSTIC FIBROSIS	6	1	\$102,650	\$1.95		5	7	1	\$119,758	\$2.79	\$2.79	-30.4%			
12	9	TRILICITY	DIABETES	191	26	\$94,131	\$1.78	\$1.76	8	237	27	\$82,215	\$1.92	\$1.92	-7.0%	0.4%		
13	77	TALTZ AUTOINJECTOR*	INFLAMMATORY CONDITIONS	38	6	\$93,078	\$1.76	\$0.36	98	19	3	\$10,917	\$0.25	\$0.25	592.5%	-10.6%		
14	12	DUPICENT PEN*	SKIN CONDITIONS	45	8	\$90,742	\$1.72	\$1.49	38	13	2	\$26,790	\$0.63	\$0.63	175.1%	23.6%		
15	5	ELIQUIS	ANTICOAGULANT	259	40	\$87,193	\$1.65	\$2.09	9	250	30	\$74,172	\$1.73	\$1.73	-4.5%	19.7%		
16	63	RIBYSELUS	DIABETE S	152	17	\$82,971	\$1.57	\$0.47	24	86	10	\$37,130	\$0.87	\$0.87	81.5%	24.3%		
17		OXERVATE*	OPHTHALMIC CONDITIONS	4	1	\$75,023	\$1.42											
18	23	VYVANSE	ATTENTION DISORDERS	232	44	\$68,714	\$1.30	\$1.03	12	194	27	\$59,834	\$1.40	\$1.40	-6.7%	-4.6%		
19		TAZVERIK*	CANCER	5	1	\$68,072	\$1.29		3	12	1	\$203,955	\$4.76	\$4.76	-72.9%			
20	114	AVONEX*	MULTIPLE SCLEROSIS	14	1	\$65,853	\$1.25	\$0.23	14	13	1	\$52,604	\$1.23	\$1.23	1.7%	-6.9%		
21	795	VUMERITY*	MULTIPLE SCLEROSIS	14	1	\$64,935	\$1.23	\$0.01	26	12	1	\$35,864	\$0.84	\$0.84	47.1%			
22	28	UBRELVY	MIGRAINE HEADACHES	70	18	\$63,935	\$1.21	\$0.94	36	38	11	\$27,302	\$0.64	\$0.64	90.2%	74.8%		
23	51	ICOSAPENT ETHYL	HIGH BLOOD CHOLESTEROL	241	36	\$63,423	\$1.20	\$0.64	25	148	25	\$36,667	\$0.86	\$0.86	40.5%	45.4%		
24	22	REXULTI	MENTAL DISEASE S	58	12	\$62,285	\$1.18	\$1.08	21	35	5	\$38,095	\$0.89	\$0.89	32.8%	17.1%		
25	101	XIAFLEX*	MISC CONDITIONS	6	3	\$61,848	\$1.17	\$0.25								13.9%		
Total Top 25:				2,639		\$2,929,990	\$55.52	\$31.31		1,469		\$1,381,025	\$32.22	\$32.22	72.3%	49.0%		
Differences Between Periods:				1,170		\$1,548,965	\$23.30	\$10.30										

*Specialty Drugs

Represents 48.9% of your total Plan Cost Net and comprises 15 indications

15 of your top 25 are specialty drugs, making up 57.6% of your Top 25 spend

Peer - 'Coalition - Level Care LLC' market segment

Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2024 Evernorth Health Services.

Express Scripts


GLP-1s

The FDA has approved the use of GLP-1s for weight loss among individuals who have a BMI of at least 30, or BMI of 27 with one other risk factor. This is approximately half of the adult population in the U.S., and very likely half of your patient population. For those on GLP-1s for weight loss, the likelihood of staying on the drug long-term varies.

Plan Cost Net Comparison



Patient Impact



Brand Name	Overall Rank	Peer Rank	Plan Cost Net	Plan Cost Net PMPM	Plan Cost Net PMPM % Change
WEGOVY	1	1	\$339,303	\$6.43	1021.6%
OZEMPIC	3	2	\$229,346	\$4.35	108.0%
MOUNJARO	4	6	\$151,127	\$2.88	1715.7%
TRULICITY	12	9	\$94,131	\$1.78	-7.0%
RYBELSUS	16	63	\$82,971	\$1.57	81.5%
SAXENDA	72	32	\$20,827	\$0.39	-55.1%
ZEPBOUND	103	159	\$12,019	\$0.23	
BYDUREON BCISE	128	264	\$7,931	\$0.15	-37.6%



GLP-1 drugs were responsible for \$937.7K, which is 14.5% of your overall cost




Double digit trend growth is expected the next few years as more GLP-1 drugs come to market.

Peer - 'Coalition - Level Care LLC' market segment
 GLP-1 - Glucagon-like Peptide-1 Receptor Agonist
 Confidential, unpublished property of Evernorth Health Services. Do not duplicate or distribute. Use and distribution limited solely to authorized personnel. © 2024 Evernorth Health Services.


Express Scripts
 By EVERNORTH



Network Utilization For Paid Claims



Utilization for Paid Claims by Network



Everyone Deserves a Healthy Smile

APPENDIX I


APPENDIX II

North Jersey Municipal Employee Benefits Fund Savings Report



Therapeutic Category	Adjudicated Amount	Participant Savings	Total Tertiary	Net Savings 75%	\$ Save per Claim	Claim Count	Participants	\$ Save PPPM (DOS)
Grand Total	\$860,129	\$48,526	\$269,955	\$406,236	\$996	408	74	\$457
Inflammatory Conditions	\$492,577	\$25,490	\$169,746	\$223,006	\$933	239	43	\$432
Asthma & Allergy	\$100,097	\$13,726	\$25,785	\$45,440	\$483	94	15	\$252
Blood Cell Deficiency	\$11,290	\$380	\$0	\$8,182	\$4,091	2	1	\$682
Cancer	\$56,241	\$1,710	\$7,067	\$35,598	\$2,738	13	3	\$989
Cystic Fibrosis	\$65,828	\$1,520	\$28,151	\$27,118	\$3,390	8	2	\$1,130
Miscellaneous Diseases	\$22,444	\$1,900	\$0	\$15,408	\$1,401	11	3	\$428
Multiple Sclerosis	\$79,500	\$3,040	\$39,206	\$27,940	\$931	30	5	\$466
Ophthalmic Conditions	\$32,153	\$760	\$0	\$23,545	\$5,886	4	1	\$1,962
Pulmonary Hypertension	\$0	\$0	\$0	\$0	\$0	7	1	\$0

Participant Count vs. \$ Save Per Participant Per Month (PPPM)



* PPPM - Per Participant Per Month

SaveOnSP | HIGHLY CONFIDENTIAL | January 30, 2024

Net Save by Drug










Therapeutic Category	Drug Name	Net Savings 75%	Participants	
Inflammatory Conditions	Stelara	\$41,402.61	7	■
	Taltz	\$35,902.44	7	■
	Enbrel	\$34,861.34	6	■
	Humira	\$30,199.57	9	■
	Otezla	\$25,925.69	6	■
	Skyrizi	\$13,314.00	3	■
	Xeljanz	\$12,307.92	2	■
	Actemra	\$9,816.30	1	■
	Benlysta	\$7,935.17	1	■
	Cimzia	\$5,496.23	1	■
	Orencia	\$3,271.75	1	■
	Rinvoq	\$2,572.50	1	■
Multiple Sclerosis	Kesimpta	\$10,767.90	1	■
	Copaxone	\$6,540.00	1	■
	Avonex	\$4,662.52	1	■
	Vumerity	\$3,379.76	1	■
	Bafiertam	\$2,589.95	1	■

Therapeutic Category	Drug Name	Net Savings 75%	Participants	
Cancer	Tazverik	\$21,167.90	1	■
	Cabometyx	\$7,215.00	1	■
	Triptodur	\$7,215.00	1	■


Net Save by Drug



Therapeutic Category	Drug Name	Net Savings 75%	Participants	
Cystic Fibrosis	Kalydeco	\$14,430.00	1	
	Trikafta	\$8,038.95	1	
	Pulmozyme	\$4,649.19	1	
Blood Cell Deficiency	Promacta	\$8,182.22	1	
Pulmonary Hypertension	Tyvaso	\$0.00	1	

Therapeutic Category	Drug Name	Net Savings 75%	Participants	
Asthma & Allergy	Dupixent	\$31,279.62	11	
	Nucala	\$7,551.00	1	
	Xolair	\$6,609.15	3	
Ophthalmic Conditions	Oxervate	\$23,544.66	1	
Miscellaneous Diseases	Ocaliva	\$7,809.42	1	
	Wakix	\$7,598.59	1	
	Austedo	\$0.00	1	

Net Save by Drug



Savings Report: Definition of Terms

(includes only claims invoiced through the SaveonSP program during the reporting period)

Adjudicated Amount: Total copay the prescription adjudicated for with Express Scripts, and therefore, amount billed to the manufacturer's copay assistance program.

Participant: Patient enrolled in SaveonSP program with a claim filled during the reporting time period

Participant Savings: Average member copay prior to SaveonSP program implementation

Total Tertiary: Used for residual member cost after copay assistance pays (\$5-\$50 generally), member's 13th fill in the year, or pass through copays

Gross Savings: Adjudicated Amount Minus Credit for Prior Copay Minus Tertiary remaining balance Minus Residual Tertiary

Net Savings: Gross Savings x 75%

Carrier Number: NJMA